Nature Progress Oncology (Запис № 579948)

МАРК-запис
000 -LEADER
fixed length control field 02201nas a22002535i 4500
001 - CONTROL NUMBER
control field 3120-421X
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20260304140725.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 251031s||||||||xxkuu poo|||||| b|EN |d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 3120-421X
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 44560
Source of number or code local
210 10 - ABBREVIATED TITLE
Abbreviated title Nat. Prog. Oncol.
245 10 - TITLE STATEMENT
Title Nature Progress Oncology
Medium [electronic resource] /
Statement of responsibility, etc edited by Nathalie Le Bot.
264 #1 -
-- London :
-- Nature Publishing Group UK :
-- Imprint: Nature Portfolio.
300 ## - PHYSICAL DESCRIPTION
Other physical details online resource.
520 ## - SUMMARY, ETC.
Summary, etc Draft: Nature Progress Oncology focuses on advancing scientific knowledge and clinical practice in the field of oncology and carcinogenesis While the journal will welcome original research and translational studies that contribute to understanding the prevention, mechanisms, diagnosis, and treatment of cancer, the journal will also encourage interdisciplinary submissions that bridge basic science and clinical application. The journal will also publish clinical trials phases I-III within oncology. Key areas of interest include, but are not limited to: Cancer Cell Biology: cellular mechanisms, metastasis and cancer stem cells. Cancer Immunology: tumour microenvironment, immunomodulation Cancer Genetics and Genomics: genetic mutations, epigenetics, genomic instability Pre-clinical Cancer Models: in vitro systems, in vivo models and translational relevance Cancer Therapy Development: immunotherapies, targeted therapies, combination treatments, therapy resistance Cancer Diagnosis and Detection: liquid biopsies, imaging innovations, biomarkers, pathology, early detection Molecular Targets and Pathways: identification and validation of molecular pathways, drug discovery Technological Innovations in Cancer: AI and machine learning, computational oncology Cancer Epidemiology: cancer incidence, risk factors, health disparities, socio-economic impacts.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cancer.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cancer Biology.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Le Bot, Nathalie.
Relator term editor.
Relator code edt
-- http://id.loc.gov/vocabulary/relators/edt
9 (RLIN) 16034
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://www.nature.com/natprogoncology">https://www.nature.com/natprogoncology</a>
Public note Open Access

Немає доступних примірників.